Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase

Autor: Vincent Servant, Arnaud Pigneux, Yohann Bohbot, Nathan Mottal, Bernard Bégaud, Noel Milpied, Aude Berroneau, Emilien Bilion, Pierre Fenaux, Ghada Miremont-Salamé, Sophie Dimicoli-Salazar, Justine Perino, Hélène Théophile, Pierre Poustis, Aude Charbonnier, Kamel Laribi, Claire Calmettes

Publikováno v: British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, Wiley, In press, 86 (5), pp.991-998. ⟨10.1111/bcp.14211⟩
Br J Clin Pharmacol

Aims Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9265840ea4d242d72fd2078599c9c8fa
https://doi.org/10.1111/bcp.14211